CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Rekah Pharmaceutical Industry Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Rekah Pharmaceutical Industry Ltd
30 Hamelach Street
Phone: +972 35581233p:+972 35581233 HOLON, 5881904  Israel Ticker: REKAREKA
Business Summary
Rekah Pharmaceutical Industry Ltd. (Rekah) is an Israel-based company which operates directly and through its subsidiaries. The Company operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The Company distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
5122 Drugs, drug proprietaries, and druggists' sundries
2834 Pharmaceutical preparations
2844 Perfumes, cosmetics, and other toilet preparations
5912 Drug stores and proprietary stores
5999 Miscellaneous retail stores, not elsewhere classified
5499 Miscellaneous food stores
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board AvrahamBiger 72 4/15/2015 4/15/2015
Chief Executive Officer, Director Arye M.Elgrably 70 4/15/2015 8/24/1993
Deputy Chief Executive Officer YuvalElgrably 38 1/1/2013 3/12/2012
10 additional Officers and Directors records available in full report.

Business Names
Business Name
REKA
Rekah Pharmaceutical Industry Ltd.
Shalpharm Medicines & Cosmetics Ltd.

General Information
Number of Employees: 434 (As of 12/31/2022)
Outstanding Shares: 11,504,022 (As of 12/31/2023)
Stock Exchange: TLV
Fax Number: +972 35565919


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024